Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.24.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
REVENUES $ 2,541 $ 845 $ 6,698 $ 4,589
COST OF REVENUES 798 619 2,792 3,043
GROSS PROFIT 1,743 226 3,906 1,546
OPERATING EXPENSES:        
Research and development expenses 543 691 1,793 2,117
Sales and marketing expenses 727 691 2,001 2,332
General and administrative expenses 790 971 2,398 2,805
Other income (163)
TOTAL OPERATING EXPENSES 2,060 2,353 6,029 7,254
OPERATING LOSS (317) (2,127) (2,123) (5,708)
Interest expense (246) (161) (590) (512)
Other Financial income, net 52 1,421 138 1,865
NET COMPREHENSIVE LOSS FOR THE PERIOD $ (511) $ (867) $ (2,575) $ (4,355)
Net loss per share attributable to common shareholders – basic (in Dollars per share) $ (0.09) $ (0.32) $ (0.59) $ (1.93)
Net loss per share attributable to common shareholders – diluted (in Dollars per share) $ (0.09) $ (0.32) $ (0.59) $ (1.93)
Weighted average number of common stocks used in computing net loss per share – basic (in Shares) 6,014,548 2,685,626 4,429,738 2,254,235
Weighted average number of common stocks used in computing net loss per share – diluted (in Shares) 6,014,548 2,685,626 4,429,738 2,254,235